---
schema_version: "secwatch.filing_event.v1"
accession: "0001096906-21-001665"
form_type: "8-K"
ticker: "UTMD"
cik: "0000706698"
company_name: "UTAH MEDICAL PRODUCTS INC"
filed_at: "2021-07-22T23:59:59+00:00"
generated_at: "2026-06-30T03:28:01.489915+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# UTMD Q2 net income up 161%, EPS $0.937; revenue $12.6M (+43%); guides FY EBITDA ~$25M

## Summary
- Q2 revenue $12.6M (+43% YoY); domestic +46%, OUS +40%; constant-currency sales +40%.
- GAAP EPS $0.937 (up 161%); non-GAAP (ex-UK DTL) EPS $1.044 (up 148%).
- Operating income $4.765M (+141%); gross margin 61.8% vs 56.3% a year ago.
- Management likely expects FY2021 adjusted EBITDA of ~$25M; TTM EBITDA $24.0M.
- Cash $59.5M, no debt; quarterly dividend $0.285/share (up from $0.280).

## SEC filing metadata
- accession: 0001096906-21-001665
- form_type: 8-K
- ticker: UTMD
- cik: 0000706698
- company_name: UTAH MEDICAL PRODUCTS INC
- filed_at: 2021-07-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01, 99.1
- EDGAR index: https://www.sec.gov/Archives/edgar/data/706698/000109690621001665/0001096906-21-001665-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/706698/000109690621001665/utmd-20210722.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001096906-21-001665
- JSON: https://secwatch.observer/filing/0001096906-21-001665.json
- Plain text: https://secwatch.observer/filing/0001096906-21-001665.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.